(Total Views: 605)
Posted On: 10/23/2020 1:42:28 PM
Post# of 148899
If true, this is great (but no real surprise).
From the other “hub” JLA Ins posted it. I really hate reposts but I am solely doing this to put on the radar given the quality of folks here. Fingers crossed
And this of course: https://m.youtube.com/watch?v=kIbEj1CIpuU
“ This is in response to your email dated August 18, 2020, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for your inquiry. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19. NIH and Operation Warp Speed (OWS) are aware of leronlimab and its potential for COVID-19 and are awaiting any promising results from the ongoing company-sponsored trial. OWS aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
DISCLAIMER: NIAID does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed on the NIAID website do not necessarily state or reflect those of the U.S. government and may not be used for advertising or product endorsement purposes. Any non-government resources are provided for your convenience. NIAID is not responsible for the availability, content, or privacy policies of non-federal organizations’ materials or websites, nor does NIAID endorse, warrant, or guarantee the products, services, or information described or offered by such organizations. Non-federal public websites do not necessarily operate under the same laws, regulations, and policies as federal websites. It is not the intention of NIAID to provide specific medical advice, but rather to provide users with information to better understand their health and their diagnosed disorders. Specific medical advice will not be provided, and NIAID urges you to consult with a qualified physician for diagnosis and for answers to your personal questions. ”
From the other “hub” JLA Ins posted it. I really hate reposts but I am solely doing this to put on the radar given the quality of folks here. Fingers crossed
And this of course: https://m.youtube.com/watch?v=kIbEj1CIpuU
“ This is in response to your email dated August 18, 2020, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for your inquiry. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19. NIH and Operation Warp Speed (OWS) are aware of leronlimab and its potential for COVID-19 and are awaiting any promising results from the ongoing company-sponsored trial. OWS aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
DISCLAIMER: NIAID does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed on the NIAID website do not necessarily state or reflect those of the U.S. government and may not be used for advertising or product endorsement purposes. Any non-government resources are provided for your convenience. NIAID is not responsible for the availability, content, or privacy policies of non-federal organizations’ materials or websites, nor does NIAID endorse, warrant, or guarantee the products, services, or information described or offered by such organizations. Non-federal public websites do not necessarily operate under the same laws, regulations, and policies as federal websites. It is not the intention of NIAID to provide specific medical advice, but rather to provide users with information to better understand their health and their diagnosed disorders. Specific medical advice will not be provided, and NIAID urges you to consult with a qualified physician for diagnosis and for answers to your personal questions. ”
(4)
(0)Scroll down for more posts ▼
